Industry supports generic substitution in England, but with some caveats
This article was originally published in Scrip
The UK R&D-based pharmaceutical industry says its support for the Department of Health's plans to introduce generic substitution in England hinges on four conditions.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.